Next Phase Newsletter

A cross-border venture capital firm founded in 2014 and is headquartered in Tokyo, Japan, with USA offices in Cambridge, MA and Seattle, WA is currently investing from their second fund of $95M. Its LPs includes some of the largest Japanese pharmaceutical companies. The firm has also launched a new life sciences incubator through which the firm seeks to nurture and advance early-stage therapeutic concepts and technologies with the goal of bringing them to a more mature stage of development. Typically, the firm makes an initial investment ranging from under $1M to $3-6M dependent on the company’s stage of development. The firm can allocate up to $16M over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide. 

The firm only invests in therapeutics and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area. 

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm based in the UK and founded in 2020 invests in women-led businesses in biosciences. The firm centers on a USD $100M fund raised as two rounds, the first having $30M to invest. The funds are focused health-tech ventures, with the main goal to hold investors and businesses accountable for diversity in management and teams. Check sizes can range between USD $350k-1.5M. The firm engages with companies in early stages and can also help identify ventures that they can back at a later stage. If the firm decides to not move forward with an investment, they are happy to support and utilize their global network to provide warm introductions to other investors and KOLs they have relationships with. The firm acts as a co-investor and will not lead. The firm is open to meeting companies based in the US, UK, Europe, Australia, and Asia. 

The firm does not invest in therapeutics and direct consumer marketing. The firm is interested in heavy sciences that have a technical element, including medical devices, diagnostics, and digital health. They may look at platforms that help identify therapeutics but will not look at pure therapeutics. The firm is indication-agnostic. The firm would like to see companies with a protectable IP. 

The firm does not require founders to be female, but require female management team members. The firm typically do not sit on board or observer seats but may if a company were to request. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A family office based in the US invests in pre-seed, seed and series A stage investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million. The firm may invest at later stages on a case-by-case basis. The firm invests across precision neuroscience, life sciences platforms, aerospace, digital deep tech, and climate tech. The firm prefers to invest in companies in conjunction with strong investment syndicate partners. The firm is open to opportunities worldwide. 
 
The firm’s life sciences funds early-stage companies across neurodegeneration, psychiatry and neurotech and also funds life science platform opportunities that raise the tide towards precision neuro. The firm invests across modalities. 
 
The firm invests in privately held companies and backs top scientists, who are pursuing breakthrough approaches rather than traditional. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm with main offices in China manages both RMB and USD funds. On average, the initial size of investment is in the $1-6M range, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm also manages innovation centers in China focusing on different special areas in Life Sciences and medical devices. With many years of operating experience of international medical technology incubators, the firm looks to tailor its services to help portfolio companies reaching key value-added milestones. The firm will consider opportunities based in China and around the globe. The firm actively supports global companies to fast land China market by leveraging the fund’s connections with leading hospitals and KOLs in China. 
 
The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, AI, and Biotechnology R&D Services. The firm is opportunistic in terms of sub-sector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. In terms of therapeutics, the firm will look at products in pre-clinical stages. Regarding medical devices and diagnostics, the firm will invest at any stage of development. 
 
The firm will invest in privately held companies only, and the firm can participate as either lead or co-investor. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital fund based in the US has invested the majority of its portfolio in the Life Sciences and HealthTech sectors. The firm plans to invest in two-or-three new portfolio companies and make one or two additional follow-on investments. The firm typically makes Pre-Seed, Seed and Series A investments ranging in size from $250K to $1M, and its largest total investment (including follow-ons) in any one company is $3.25M.  
 
The firm invests primarily in the Life Sciences and HealthTech sectors and in a wide range of sub-sectors within those sectors. The firm is sector and subsector agnostic and is open to evaluating different types of technologies. 
 
The firm invests in companies with growth-minded founders with proven track records, defensible market positions, and the ability to be positive cash-flow within 12-24 months. The firm is minority-owned and is committed to managing a diverse portfolio of companies with the potential to deliver above-average returns, including companies with minority, female and SEDI founders. The firm is an active investor that can provide valuable de-risking strategic and operational guidance and support through its venture studio, which helps portfolio companies reduce the risk of costly mistakes, get to market sooner and scale faster. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Founded in 2019, a Chinese venture capital firm is specialized in the growth-stage life science investments and IT area. Currently, the firm has 300M RMB assets under management. While generally being flexible on the allocation size, the firm typically makes investments ranging from 10-60 MM RMB (~1.4-8.5 MM USD). 
 
The firm has strong interest in investing novel pharmaceuticals, including orphan drugs. Also, the firm is open to digital health, especially the ones has big data application in life science area. So far, the firm has no interest in diagnostics nor medical devices products. 
 
The firm prefers companies with a China Angle, especially the ones open to register an entity in China. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A globally diversified healthcare venture capital firm has a mission is to deliver medical solutions and savings to over 100M people around the world. The firm seeks out visionary entrepreneurs who combine integrity, intelligence, and passion to address pressing healthcare challenges innovatively and ethically. The firm’s globally diversified portfolio comprises 60% allocation in the U.S. and the remaining 40% distributed across Singapore, India, and the EU. The firm’s engagement extends beyond financial investment. The firm provides robust post-investment support, focusing on strategy development, distribution, cross-border expansion, and manufacturing/OEM partnerships. They strive to establish an ecosystem that fosters collaboration among start-ups, government bodies, clinical, investment, and commercial partners. This approach ensures that portfolio companies receive comprehensive support, aiding in their growth and impactful contribution to the healthcare sector. 
 
Focused on early to growth-stage investments, the firm specializes in sectors including medical devices, digital health, healthcare services, and AI-empowered solutions. The firm has particular interests in critical areas such as oncology, ophthalmology, brain health, orthopedics, cardiology, and other chronic diseases management. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.